References
- Talpaz M, Mavligit G, Keating M, Walters R S, Gutterman J U. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med 1983; 99: 789–792
- Talpaz M, Kantarjian H M, McCredie K, Trujillo J M, Keating M J, Gutterman J U. Hematologic remission and cytogenetic improvement induced by recombinant human interferon-α-A in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065–1069
- Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau J L, Maloisel F, et al. Interferon alfa-2B combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337: 223–229
- O'Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
- Lipton J H, Khoroshko N, Golenkov A, Abdulkadyrov K, Nair K, Raghunadharao D, et al. Phase II, randomized, multicenter, comparative study of peginterferon-α-2a (40 kD) (Pegasys®) versus interferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma 2007; 48(3)497–505
- Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver R, et al. Pegylated recombinant interferon α-2b vs recombinant interferon α-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 2004; 18: 309–315
- Quintás-Cardama A, Kantarjian H M, Ravandi F, Garcia-Manero G, O'Brien S, Verstovsek S, et al. Immune modulation of minimal residual disease in patients with chronic myelogenous leukemia in early chronic phase: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated-interferon and GM-CSF. Blood 2006; 108: 2207, (abstract)